NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more
NeuroMetrix Inc (NURO) - Net Assets
Latest net assets as of March 2025: $14.31 Million USD
Based on the latest financial reports, NeuroMetrix Inc (NURO) has net assets worth $14.31 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.32 Million) and total liabilities ($1.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.31 Million |
| % of Total Assets | 93.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | 172.72% |
| 10-Year Change | 13.92% |
| Growth Volatility | 103.63 |
NeuroMetrix Inc - Net Assets Trend (2002–2024)
This chart illustrates how NeuroMetrix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NeuroMetrix Inc (2002–2024)
The table below shows the annual net assets of NeuroMetrix Inc from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.31 Million | -28.77% |
| 2023-12-31 | $20.09 Million | -13.98% |
| 2022-12-31 | $23.36 Million | +0.60% |
| 2021-12-31 | $23.22 Million | +342.39% |
| 2020-12-31 | $5.25 Million | +107.40% |
| 2019-12-31 | $2.53 Million | -58.51% |
| 2018-12-31 | $6.10 Million | +21.53% |
| 2017-12-31 | $5.02 Million | +1.14% |
| 2016-12-31 | $4.96 Million | -60.51% |
| 2015-12-31 | $12.56 Million | +270.90% |
| 2014-12-31 | $3.39 Million | -52.92% |
| 2013-12-31 | $7.19 Million | -18.24% |
| 2012-12-31 | $8.80 Million | -20.63% |
| 2011-12-31 | $11.09 Million | -45.10% |
| 2010-12-31 | $20.20 Million | -43.44% |
| 2009-12-31 | $35.71 Million | +56.40% |
| 2008-12-31 | $22.83 Million | -51.14% |
| 2007-12-31 | $46.73 Million | +7.65% |
| 2006-12-31 | $43.41 Million | +19.75% |
| 2005-12-31 | $36.25 Million | +6.44% |
| 2004-12-31 | $34.06 Million | +174.85% |
| 2003-12-31 | $-45.50 Million | -13.96% |
| 2002-12-31 | $-39.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NeuroMetrix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17805549000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $205.00 | 0.00% |
| Other Comprehensive Income | $60.95K | 0.43% |
| Other Components | $232.17 Million | 1622.22% |
| Total Equity | $14.31 Million | 100.00% |
NeuroMetrix Inc Competitors by Market Cap
The table below lists competitors of NeuroMetrix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ADVFN Plc
PINK:AVFCF
|
$6.96 Million |
|
UMediC Group Berhad
KLSE:0256
|
$6.96 Million |
|
Pool Advista Indonesia Tbk
JK:POOL
|
$6.96 Million |
|
Curative Biotechnology Inc
NYSE MKT:CUBT
|
$6.96 Million |
|
IERVOLINO ENTERTAINMENT
F:G37
|
$6.95 Million |
|
Thai Nam Plastic Public Company Limited
BK:TNPC
|
$6.95 Million |
|
GUNA
JK:GUNA
|
$6.95 Million |
|
Yunji Inc
NASDAQ:YJ
|
$6.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NeuroMetrix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,091,317 to 14,311,651, a change of -5,779,666 (-28.8%).
- Net loss of 7,806,055 reduced equity.
- New share issuances of 1,476,301 increased equity.
- Other comprehensive income decreased equity by 179,222.
- Other factors increased equity by 729,310.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.81 Million | -54.54% |
| Share Issuances | $1.48 Million | +10.32% |
| Other Comprehensive Income | $-179.22K | -1.25% |
| Other Changes | $729.31K | +5.1% |
| Total Change | $- | -28.77% |
Book Value vs Market Value Analysis
This analysis compares NeuroMetrix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $-39769.41 | $4.58 | x |
| 2003-12-31 | $-45321.04 | $4.58 | x |
| 2004-12-31 | $32620.99 | $4.58 | x |
| 2005-12-31 | $32163.32 | $4.58 | x |
| 2006-12-31 | $38211.78 | $4.58 | x |
| 2007-12-31 | $42636.74 | $4.58 | x |
| 2008-12-31 | $19154.82 | $4.58 | x |
| 2009-12-31 | $24526.01 | $4.58 | x |
| 2010-12-31 | $10109.60 | $4.58 | x |
| 2011-12-31 | $5524.92 | $4.58 | x |
| 2012-12-31 | $1315.46 | $4.58 | x |
| 2013-12-31 | $387.26 | $4.58 | x |
| 2014-12-31 | $132.95 | $4.58 | x |
| 2015-12-31 | $248.32 | $4.58 | x |
| 2016-12-31 | $59.28 | $4.58 | x |
| 2017-12-31 | $29.49 | $4.58 | x |
| 2018-12-31 | $4.39 | $4.58 | x |
| 2019-12-31 | $20.91 | $4.58 | x |
| 2020-12-31 | $1.38 | $4.58 | x |
| 2021-12-31 | $9.05 | $4.58 | x |
| 2022-12-31 | $26.21 | $4.58 | x |
| 2023-12-31 | $19.28 | $4.58 | x |
| 2024-12-31 | $7.27 | $4.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NeuroMetrix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -257.38%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.07x
- Recent ROE (-54.54%) is above the historical average (-75.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | -113.45% | 0.60x | 0.00x | $-800.61K |
| 2003 | 0.00% | -40.00% | 1.27x | 0.00x | $883.52K |
| 2004 | -12.58% | -23.91% | 0.47x | 1.11x | $-7.69 Million |
| 2005 | 2.59% | 2.74% | 0.80x | 1.18x | $-2.69 Million |
| 2006 | 9.83% | 7.72% | 0.99x | 1.28x | $-73.05K |
| 2007 | -17.93% | -18.78% | 0.79x | 1.21x | $-13.05 Million |
| 2008 | -121.45% | -89.10% | 0.99x | 1.37x | $-30.01 Million |
| 2009 | -33.37% | -45.60% | 0.64x | 1.14x | $-15.49 Million |
| 2010 | -83.62% | -121.52% | 0.60x | 1.14x | $-18.91 Million |
| 2011 | -90.01% | -96.00% | 0.73x | 1.28x | $-11.09 Million |
| 2012 | -113.72% | -132.11% | 0.70x | 1.24x | $-10.89 Million |
| 2013 | -111.45% | -151.91% | 0.49x | 1.50x | $-8.74 Million |
| 2014 | -229.29% | -140.88% | 0.48x | 3.37x | $-8.10 Million |
| 2015 | -73.13% | -125.86% | 0.46x | 1.28x | $-10.44 Million |
| 2016 | -300.62% | -123.99% | 1.45x | 1.67x | $-15.41 Million |
| 2017 | -256.29% | -75.23% | 1.78x | 1.91x | $-13.36 Million |
| 2018 | 0.39% | 0.15% | 1.33x | 1.99x | $-586.18K |
| 2019 | -144.22% | -39.35% | 1.35x | 2.72x | $-3.90 Million |
| 2020 | -38.15% | -27.14% | 0.92x | 1.52x | $-2.53 Million |
| 2021 | -9.50% | -26.72% | 0.33x | 1.07x | $-4.53 Million |
| 2022 | -18.70% | -52.90% | 0.33x | 1.06x | $-6.70 Million |
| 2023 | -32.50% | -110.64% | 0.28x | 1.07x | $-8.54 Million |
| 2024 | -54.54% | -257.38% | 0.20x | 1.07x | $-9.24 Million |
Industry Comparison
This section compares NeuroMetrix Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NeuroMetrix Inc (NURO) | $14.31 Million | 0.00% | 0.07x | $6.95 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |